Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1183/09059180.00007909 http://scihub22266oqcxt.onion/10.1183/09059180.00007909 20956169!9491640!20956169     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Eur+Respir+Rev 2010 ; 19 (115): 68-71 Nephropedia Template TP {{tp|p=20956169|t=2010. Riociguat: an upcoming therapy in chronic thromboembolic pulmonary hypertension?|pdf=|usr=}}{{20956169}} gab.com Text Riociguat: an upcoming therapy in chronic thromboembolic pulmonary hypertension JO: Eur Respir Rev http://www.kidney.de/pget.php?&tw=1&pmid=20956169 #FOAvip Although pulmonary endarterectomy remains the treatment of choice for patients with chronic thromboembolic pulmonary hypertension (CTEPH), not all patients will benefit from or receive this highly specialised surgery. Patients whose CTEPH is deemed inoperable by an experienced centre and patients with persistent pulmonary hypertension after surgery are candidates for trial of pulmonary arterial hypertension (PAH) specific pharmacotherapies. However, the currently available PAH specific pharmacotherapies have not demonstrated a clear benefit in either of these patient groups. Accordingly, PAH therapies remain off-label for use in CTEPH. Riociguat (BAY 63-2521) is a stimulator of soluble guanylate cyclase, and may represent a novel agent in the treatment of select patients with CTEPH. Pre-clinical and human phase II studies with riociguat have reported promising results, and a multinational, randomised, controlled, double-blinded phase III study is currently underway to investigate the effect of riociguat in patients with inoperable CTEPH and those with persistent or recurrent pulmonary hypertension following pulmonary endarterectomy. Twit Text FOAVip Riociguat: an upcoming therapy in chronic thromboembolic pulmonary hypertension ????Eur Respir Rev http://www.kidney.de/pget.php?&tw=1&pmid=20956169 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=20956169 #FOAvip English Wikipedia <ref>{{Cite pmid|20956169}}</ref> Riociguat: an upcoming therapy in chronic thromboembolic pulmonary hypertension? #MMPMID20956169 Kim NH Eur Respir Rev 2010[Mar]; 19 (115): 68-71 PMID20956169show ga Although pulmonary endarterectomy remains the treatment of choice for patients with chronic thromboembolic pulmonary hypertension (CTEPH), not all patients will benefit from or receive this highly specialised surgery. Patients whose CTEPH is deemed inoperable by an experienced centre and patients with persistent pulmonary hypertension after surgery are candidates for trial of pulmonary arterial hypertension (PAH) specific pharmacotherapies. However, the currently available PAH specific pharmacotherapies have not demonstrated a clear benefit in either of these patient groups. Accordingly, PAH therapies remain off-label for use in CTEPH. Riociguat (BAY 63-2521) is a stimulator of soluble guanylate cyclase, and may represent a novel agent in the treatment of select patients with CTEPH. Pre-clinical and human phase II studies with riociguat have reported promising results, and a multinational, randomised, controlled, double-blinded phase III study is currently underway to investigate the effect of riociguat in patients with inoperable CTEPH and those with persistent or recurrent pulmonary hypertension following pulmonary endarterectomy. |Chronic Disease[MESH] |Guanylate Cyclase[MESH] |Humans[MESH] |Hypertension, Pulmonary/*drug therapy[MESH] |Pulmonary Circulation/drug effects[MESH] |Pulmonary Embolism/*drug therapy[MESH] |Pyrazoles/*therapeutic use[MESH] |Pyrimidines/*therapeutic use[MESH] |Receptors, Cytoplasmic and Nuclear/*agonists[MESH]Riociguat: an upcoming therapy in chronic thromboembolic pulmonary hyp(epmc).pdf DeepDyve Pubget Overpricing